FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022293788> ?p ?o ?g. }

• W2022293788 endingPage "1055" @default.
• W2022293788 startingPage "1050" @default.
• W2022293788 abstract "The aim of this study was to compare the efficacy and safety of induction treatment with antithymocyte globulins (ATG) followed by tacrolimus therapy with immediate tacrolimus therapy in renal transplant recipients.This 12-month, open, prospective study was conducted in 15 centers in France and 1 center in Belgium; 309 patients were randomized to receive either induction therapy with ATG (n=151) followed by initiation of tacrolimus on day 9 or immediate tacrolimus-based triple therapy (n=158). In both study arms, the initial daily tacrolimus dose was 0.2 mg/kg. Steroid boluses were given in the first 2 days and tapered thereafter from 20 mg/day to 5 mg/day. Azathioprine was administered at 1-2 mg/kg per day.At month 12, biopsy-confirmed acute rejections were reported for 15.2% (induction) and 30.4% (noninduction) of patients (P=0.001). The incidence of steroid-sensitive acute rejections was 7.9% (induction) and 22.2% (noninduction)(P=0.001). Steroid-resistant acute rejections were reported for 8.6% (induction) and 8.9% (noninduction) of patients. A total of nine patients died. Patient survival and graft survival at month 12 was similar in both treatment groups (97.4% vs. 96.8% and 92.1% vs. 91.1%, respectively). Statistically significant differences in the incidence of adverse events were found for cytomegalovirus (CMV) infection (induction, 32.5% vs. noninduction, 19.0%, P=0.009), leukopenia (37.3% vs. 9.5%, P<0.001), fever (25.2% vs. 10.1%, P=0.001), herpes simplex (17.9% vs. 5.7%, P=0.001), and thrombocytopenia (11.3% vs. 3.2%, P=0.007). In the induction group, serum sickness was observed in 10.6% of patients. The incidence of new onset diabetes mellitus was 3.4% (induction) and 4.5% (noninduction).Low incidences of acute rejection were found in both treatment arms. Induction treatment with ATG has the advantage of a lower incidence of acute rejection, but it significantly increases adverse events, particularly CMV infection." @default.
• W2022293788 created "2016-06-24" @default.
• W2022293788 creator A5003294082 @default.
• W2022293788 creator A5004312082 @default.
• W2022293788 creator A5010867268 @default.
• W2022293788 creator A5012878862 @default.
• W2022293788 creator A5020871132 @default.
• W2022293788 creator A5025700937 @default.
• W2022293788 creator A5029740518 @default.
• W2022293788 creator A5035060087 @default.
• W2022293788 creator A5035945757 @default.
• W2022293788 creator A5037176928 @default.
• W2022293788 creator A5038248105 @default.
• W2022293788 creator A5038501867 @default.
• W2022293788 creator A5040281183 @default.
• W2022293788 creator A5045454594 @default.
• W2022293788 creator A5047404762 @default.
• W2022293788 creator A5048019514 @default.
• W2022293788 creator A5050643650 @default.
• W2022293788 creator A5051163337 @default.
• W2022293788 creator A5053697327 @default.
• W2022293788 creator A5056349922 @default.
• W2022293788 creator A5056383277 @default.
• W2022293788 creator A5060790711 @default.
• W2022293788 creator A5060881051 @default.
• W2022293788 creator A5061575721 @default.
• W2022293788 creator A5062304111 @default.
• W2022293788 creator A5064225370 @default.
• W2022293788 creator A5066608092 @default.
• W2022293788 creator A5070733450 @default.
• W2022293788 creator A5071050458 @default.
• W2022293788 creator A5071457248 @default.
• W2022293788 creator A5083051503 @default.
• W2022293788 creator A5083674552 @default.
• W2022293788 creator A5086162029 @default.
• W2022293788 creator A5086557690 @default.
• W2022293788 date "2001-09-01" @default.
• W2022293788 modified "2023-10-10" @default.
• W2022293788 title "INDUCTION VERSUS NONINDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH TACROLIMUS-BASED IMMUNOSUPPRESSION1" @default.
• W2022293788 cites W1963731157 @default.
• W2022293788 cites W1979737218 @default.
• W2022293788 cites W1999246730 @default.
• W2022293788 cites W2002358655 @default.
• W2022293788 cites W2014605498 @default.
• W2022293788 cites W2027371366 @default.
• W2022293788 cites W2031727025 @default.
• W2022293788 cites W2044600432 @default.
• W2022293788 cites W2052447012 @default.
• W2022293788 cites W2066836576 @default.
• W2022293788 cites W2075271694 @default.
• W2022293788 cites W2093603781 @default.
• W2022293788 cites W2109528079 @default.
• W2022293788 cites W2121454052 @default.
• W2022293788 cites W2151035710 @default.
• W2022293788 cites W4301325158 @default.
• W2022293788 doi "https://doi.org/10.1097/00007890-200109270-00012" @default.
• W2022293788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11579299" @default.
• W2022293788 hasPublicationYear "2001" @default.
• W2022293788 type Work @default.
• W2022293788 sameAs 2022293788 @default.
• W2022293788 citedByCount "166" @default.
• W2022293788 countsByYear W20222937882012 @default.
• W2022293788 countsByYear W20222937882013 @default.
• W2022293788 countsByYear W20222937882014 @default.
• W2022293788 countsByYear W20222937882015 @default.
• W2022293788 countsByYear W20222937882016 @default.
• W2022293788 countsByYear W20222937882017 @default.
• W2022293788 countsByYear W20222937882018 @default.
• W2022293788 countsByYear W20222937882019 @default.
• W2022293788 countsByYear W20222937882020 @default.
• W2022293788 countsByYear W20222937882021 @default.
• W2022293788 countsByYear W20222937882022 @default.
• W2022293788 countsByYear W20222937882023 @default.
• W2022293788 crossrefType "journal-article" @default.
• W2022293788 hasAuthorship W2022293788A5003294082 @default.
• W2022293788 hasAuthorship W2022293788A5004312082 @default.
• W2022293788 hasAuthorship W2022293788A5010867268 @default.
• W2022293788 hasAuthorship W2022293788A5012878862 @default.
• W2022293788 hasAuthorship W2022293788A5020871132 @default.
• W2022293788 hasAuthorship W2022293788A5025700937 @default.
• W2022293788 hasAuthorship W2022293788A5029740518 @default.
• W2022293788 hasAuthorship W2022293788A5035060087 @default.
• W2022293788 hasAuthorship W2022293788A5035945757 @default.
• W2022293788 hasAuthorship W2022293788A5037176928 @default.
• W2022293788 hasAuthorship W2022293788A5038248105 @default.
• W2022293788 hasAuthorship W2022293788A5038501867 @default.
• W2022293788 hasAuthorship W2022293788A5040281183 @default.
• W2022293788 hasAuthorship W2022293788A5045454594 @default.
• W2022293788 hasAuthorship W2022293788A5047404762 @default.
• W2022293788 hasAuthorship W2022293788A5048019514 @default.
• W2022293788 hasAuthorship W2022293788A5050643650 @default.
• W2022293788 hasAuthorship W2022293788A5051163337 @default.
• W2022293788 hasAuthorship W2022293788A5053697327 @default.
• W2022293788 hasAuthorship W2022293788A5056349922 @default.
• W2022293788 hasAuthorship W2022293788A5056383277 @default.
• W2022293788 hasAuthorship W2022293788A5060790711 @default.
• W2022293788 hasAuthorship W2022293788A5060881051 @default.
• W2022293788 hasAuthorship W2022293788A5061575721 @default.

• next